Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Filings indexed 212 across all filing types
Latest filing 2024-11-29 Capital/Financing Update
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a detailed announcement by Hemostemix Inc. regarding the closing of a private placement financing, including tranche details, warrant issuance, gross proceeds, use of funds, and regulatory approvals. It is focused on the company’s fundraising and capital structure update, matching the Capital/Financing Update category.
2024-11-29 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2024-11-13 English
News release - English.pdf
Regulatory Filings
2024-10-11 English
News release - English.pdf
Regulatory Filings
2024-08-02 English
News release - English.pdf
Regulatory Filings
2024-02-06 English
News release - English.pdf
Regulatory Filings
2024-01-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.